Introduction
Mutations in p53 have been found in ~50% of sporadic human cancers 1 . Moreover, inherited mutations in one p53 allele cause Li-Fraumeni syndrome (LFS), a rare autosomal disorder characterized by development of diverse cancer types at a young age after loss of the wt p53 allele 2,3 . p53 is a transcription factor that controls diverse cellular responses to stress, including proliferation arrest, senescence and apoptosis, by direct regulation of ~200 target genes 4 . Mice with homozygous germline loss or mutation of p53 develop tumors (mostly thymic lymphomas) with 100% incidence within 300 days [5] [6] [7] [8] .
Evasion of cell death is a prerequisite for the development of cancer. Apoptosis is a genetically programmed process for the killing of cells that are no longer needed or potentially dangerous 9, 10 . Mutations or epigenetic changes in regulators of apoptosis cause or contribute to the development of several diseases, particularly cancer, and render malignant cells resistant to a broad range of chemotherapeutic drugs. The BCL-2-regulated apoptotic pathway can be activated by developmental cues or a diverse range of stress stimuli (e.g. cytokine withdrawal, oncogene activation, DNA damage). This pathway is controlled by the three subgroups of the BCL-2 protein . The pro-apoptotic multi-BH (BCL-2 Homology) domain proteins BAX and BAK are required for activation of the downstream phases of apoptosis: mitochondrial outer membrane permeabilization (MOMP) and consequent caspase activation 12, 13 . The BH3-only proteins bind to the pro-survival BCL-2 family proteins to unleash primed BAX/BAK allowing them to cause MOMP. Certain BH3-only proteins (e.g. BIM, PUMA) can also activate BAX/BAK through direct binding 14, 15 .
Although it has long been known that over-expression of BCL-2 (or its pro-survival relatives) can promote tumorigenesis, researchers have only recently started to explore which pro-survival BCL-2 family member expressed under endogenous control is required for the development and sustained expansion of which tumor.
BCL-XL 16,17 but not BCL-2 18 is essential for the development of MYC-driven pre-B/B lymphoma, whereas MCL-1 is critical for the development of AML 19, 20 . Such information provided the impetus for the development of inhibitors of pro-survival BCL-2 family members ('BH3-mimetics' navitoclax/ABT-263: inhibits BCL-2, BCL-XL and BCL-W; ABT-199: inhibits only BCL-2) 10 .
In this study we examined the impact of loss of BCL-XL or MCL-1 on the development and sustained growth of thymic lymphoma elicited by loss of p53 and
show that only MCL-1 is critical.
Materials and methods

Mice
Experiments with mice were conducted according to the guidelines of the Walter and , Lck-Cre
23
, Rosa26CreERT2 24 and p53 -/-6 mice (all maintained on a C57BL/6-Ly5.2 background) have been described previously.
Transplantation studies
For transplantation studies six C57BL/6-Ly5.1 recipient mice were injected intraperitoneally (i.p.) with 3x10 6 thymic lymphoma cells (TCRβ + CD4 + CD8 + Ly5.2 + ). A total of 3-6 independent thymic lymphoma samples were tested. Three of the recipient mice were treated by oral gavage with 4 mg tamoxifen/day (in peanut oil 25 ) on day 7 and day 8 (the remaining three recipients were left untreated) and then monitored for lymphoma development. Mice that had developed lymphoma were sacrificed and the lymphomas analyzed by FACS analysis and Western blotting. The experiment was concluded at 90 days after lymphoma injection. Mice bearing lymphoma were examined for organ weights.
We utilized the loxP-targeted Bcl-x conditional knock-out mouse model to determine the role of BCL-XL in tumorigenesis caused by loss of p53. Figure 1C ). These lymphomas did not show consistent alterations in the expression of other pro-survival (BCL-2, MCL-1) or pro-apoptotic (BIM, PUMA) BCL-2 family members examined ( Figure 1C ).
These results demonstrate that BCL-XL is not required for the development of thymic lymphoma or other cancers elicited by loss of p53.
Constitutive loss of a single allele of Mcl-1 significantly delays thymic lymphoma development in p53 -/-mice
Since most thymic lymphomas in p53 -/-mice express readily detectable levels of MCL-1 ( Figure 1C ), we generated p53-deficient mice that lack one allele of Mcl-1 Figure 2D ). These results show that loss of a single allele of Mcl-1 can markedly delay the development of thymic lymphoma that is initiated by loss of p53.
Impact of conditional deletion of one or both alleles of Mcl-1 on T cell lymphoma development in p53 -/-mice
The ability of loss of one allele of Mcl-1 to significantly delay lymphoma development in p53 -/-mice could be due to an impact on cells undergoing neoplastic transformation during T lymphoid differentiation or might be a consequence of defects in the survival of more primitive hematopoietic stem/progenitor cells, known to be the cells of origin of γ-radiation-induced thymic lymphoma 28, 29 . Furthermore, Lck-Cre;Mcl-1 fl/fl mice present with a significant reduction of immature and mature T cells in the thymus suggesting MCL-1 is critical for T cell development (supplemental Figure 4A ,B) 30 .
We generated p53 Figure 3A ), but we did observe a ~50% reduction in thymic lymphoma incidence with a concomitant increase in sarcoma and certain other pathologies ( Figure 3B Figure 3C ). The others were hCD4 -(see tumor #728 in Figure 3C ) and thus had been selected against loss of even a single Mcl-1 allele. Accordingly, Western blotting showed that tumor #692 expressed only low levels of MCL-1 whereas tumor #728 had higher levels of MCL-1 (note that the MCL-1 protein encoded by the Mcl-1 fl allele runs with slightly higher molecular weight than MCL-1 protein encoded by the wild-type allele 26 , Figure 3D ). The hCD4-positive lymphomas expressing low levels of MCL-1 appeared to be selected for reduced levels of pro-apoptotic BIM. There were no consistent differences in the expression of BCL-XL, BCL-2 or PUMA between the different lymphomas ( Figure 3D ). Figure 4A ). Figure 4B ). Post-mortem analysis of sick tumor-bearing mice did not reveal any significant differences between the two genotypes in terms of thymus or spleen weights (supplemental Figure 4A, Figure 4D ). alleles, whereas the remainder were left untreated ( Figure 5A ). These recipients were monitored for lymphoma growth over a 90-day period.
Mice that were injected with p53 -/-;RosaCreERT2 thymic lymphoma cells and then treated with tamoxifen (median survival 35 days) survived slightly longer than their untreated counterparts (median survival 32 days), demonstrating that Crerecombinase induction has only minor cytotoxic impact on these lymphomas in vivo.
Tamoxifen-treated mice bearing p53 Western blot analysis showed that p53 -/-;RosaCreERT2;Mcl-1 fl/+ lymphomas that were isolated from recipients that had been treated with tamoxifen had slightly lower levels of MCL-1 compared to the same lymphoma collected from untreated control recipients ( Figure 6B ). This indicates that p53 -/-lymphomas can survive and expand with a minor reduction in MCL-1 but not in the complete absence of this pro-survival protein.
Collectively, these results demonstrate that MCL-1 is essential for the sustained survival and expansion of p53 -/-thymic lymphomas. For the development of novel therapeutic strategies it is essential to know which prosurvival BCL-2 family member is critical for the sustained survival and expansion of a particular tumor. This can be investigated by using specific drugs (if they exist, such as ABT-199 to inhibit BCL-2) or by conditional deletion of pro-survival Bcl-2 family genes in malignant tumors by using the tamoxifen regulated CreERT2 recombinase.
By performing tumor transplant experiments and then inducing acute deletion of either Mcl-1 or Bcl-x floxed alleles we found that MCL-1 but not BCL-XL is critical for sustained survival and expansion of p53-deficient thymic lymphomas. This is reminiscent of previous reports, which showed that MCL-1 is also critical for the 
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